You are here

Phase 2 Trial of SGN-30 Initiated, Treatment of Primary Cutaneous Anaplastic Large Cell Lymphoma

BOTHELL, Wash.--(BUSINESS WIRE)--Sept. 23, 2004--Seattle Genetics, Inc. (Nasdaq:SGEN - News) announced today that it has initiated a phase II clinical trial of SGN-30 for the treatment of primary cutaneous anaplastic large cell lymphoma (ALCL). Primary cutaneous ALCL, which is a type of non-Hodgkin's lymphoma that involves the skin, is the company's third clinical indication for SGN-30. The phase II study is designed to evaluate the antitumor activity and tolerability of SGN-30 in up to 40 patients who have relapsed or are resistant to prior therapies.

Seattle Genetics is conducting additional phase II studies of SGN-30 in Hodgkin's disease and systemic ALCL. The company has reported data from the first five systemic ALCL patients treated with SGN-30, noting that objective responses were observed in two patients. Seattle Genetics plans to report additional preliminary data from these ongoing phase II studies at the American Society for Hematology (ASH) Annual Meeting in December 2004.

"We are optimistic about the therapeutic potential of SGN-30 in ALCL and believe it may offer a rapid path to regulatory approval," stated Dr. Michael McDonald, Chief Medical Officer of Seattle Genetics. "We are also conducting clinical trials of SGN-30 in Hodgkin's disease as a single agent and are planning future studies in combination with chemotherapy."

SGN-30 is a genetically engineered monoclonal antibody that targets CD30-positive hematologic malignancies, including Hodgkin's disease and certain types of lymphomas and leukemias. The company has received orphan drug designations from the FDA for SGN-30 in both Hodgkin's disease and T-cell lymphomas, a category that includes ALCL. Seattle Genetics is also conducting preclinical studies to evaluate the potential of SGN-30 in the treatment of immunologic diseases.

About ALCL
Anaplastic large cell lymphoma (ALCL) is a type of T-cell non-Hodgkin's lymphoma. According to the American Cancer Society, approximately 54,300 new cases of non-Hodgkin's lymphoma, of which an estimated 15% are of T-cell origin, will be diagnosed in the United States during 2004. Most ALCL cases fall into one of two distinct forms: systemic ALCL, involving lymph nodes or extranodal sites; or primary cutaneous ALCL, involving skin nodules. For more information about ALCL, visit www.alcl.com.

Source: Seattle Genetics, Inc.

Recent Headlines

Antibiotics, Statins, and Glucocorticoids All Show Promise
Possible First Treatment Option for Rare Autoimmune Disease of the CNS
New Hematologic Biomarker Test Provides New Approach to Sepsis Triage and Diagnosis
Current, Sole Therapy Not Always Successful/Suitable
Over 1.5 Million Americans Likely to have Wet AMD by 2020 
Potential For Use Against E. Coli, TB, Resistant Bacteria
More Than 32% of Patients Responded in Trial